WE HAVE 2 NEW TYSABRI EDITORS STARTING 4/15/10! THEY WIL BE POSTING TYSABRI NEWS EVERY DAY!
Wednesday, May 14
Biogen Leverages Strength In MS Treatments
By
the end of the third quarter, Biogen's multiple sclerosis treatments
Avonex, Tysabri, and Tecfidera had racked up $3.94 billion in sales so
far for the year — about 80% of total revenue. READ MORE